Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Non-Whites remain sorely underrepresented in phase 3 psoriasis trials

Key clinical point: There are very limited data from phase 3 trials to judge racial differences in response to therapies for psoriasis.

Major finding: Of psoriasis trials with ethnoracial data, 85.8% of participants were White, 19.5% were Hispanic, 9.2% were Asian, and 3.1% were black.

Data source: A cross-sectional analysis of the database.

Disclosures: The research had no funding source. Three of the nine authors reported financial relationships with pharmaceutical companies.


Reddy VD et al. Br J Dermatol. 2020 Sep 17. doi: 10.1111/bjd.19468.